BioMarin's Q4 performance mixed, stock price slightly down

2026-02-23 23:28:20

San Rafael, California - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its fourth-quarter results that missed earnings expectations but exceeded analyst estimates for revenue. Following the announcement, the stock price fell 0.5%.

The biotech company’s adjusted earnings per share for the fourth quarter were $0.46, below the consensus analyst expectation of $0.77. Revenue reached $875 million, surpassing the estimated $829.31 million and representing a 17% increase from $747 million in the same period last year. The earnings miss was mainly due to a $119 million inventory write-down related to the company’s voluntary withdrawal of ROCTAVIAN from the market.

BioMarin President and CEO Alexander Hardy stated, “In 2025, excellent operations led to stronger financial performance, including double-digit revenue growth, robust profitability, and increasing cash flow.”

Full-year 2025 revenue grew 13% year-over-year to $3.2 billion, with enzyme therapy revenue up 9% and VOXZOGO increasing 26%. The revenue growth in the fourth quarter was primarily driven by VOXZOGO, which generated $273 million, a 31% increase year-over-year, while enzyme therapy revenue grew 13% to $549 million.

BioMarin’s guidance for 2026 does not include any contribution from its announced acquisition of Amicus Therapeutics, which is expected to close in the second quarter. The company expects full-year adjusted earnings per share between $4.95 and $5.15, below the analyst consensus of $5.33. The median of $5.05 is 5.3% lower than expected. Revenue guidance is between $3.325 billion and $3.425 billion, compared to the market consensus of $3.378 billion, with a median of $3.375 billion slightly below expectations.

The company reported a full-year operating cash flow of $828 million for 2025, with cash and investments at the end of the year approximately $2 billion.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.